AbCellera Biologics (NASDAQ:ABCL – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect AbCellera Biologics to post earnings of ($0.14) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
AbCellera Biologics Trading Up 6.8 %
Shares of NASDAQ ABCL opened at $5.46 on Tuesday. The stock has a market cap of $1.58 billion, a P/E ratio of -12.13 and a beta of 0.38. AbCellera Biologics has a 12-month low of $3.87 and a 12-month high of $10.21. The business’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $5.12.
Hedge Funds Weigh In On AbCellera Biologics
Hedge funds have recently made changes to their positions in the company. Worth Asset Management LLC purchased a new position in shares of AbCellera Biologics during the first quarter worth about $25,000. Point72 Asset Management L.P. purchased a new position in shares of AbCellera Biologics during the second quarter worth about $26,000. Point72 Middle East FZE purchased a new position in shares of AbCellera Biologics during the second quarter worth about $30,000. Belpointe Asset Management LLC grew its holdings in shares of AbCellera Biologics by 55.7% during the first quarter. Belpointe Asset Management LLC now owns 5,300 shares of the company’s stock worth $40,000 after buying an additional 1,896 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in shares of AbCellera Biologics by 56.1% during the second quarter. Citigroup Inc. now owns 8,021 shares of the company’s stock worth $52,000 after buying an additional 2,884 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.
Wall Street Analyst Weigh In
About AbCellera Biologics
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
- Five stocks we like better than AbCellera Biologics
- Conference Calls and Individual Investors
- 3 attractive stocks that insiders are buying
- 3 Warren Buffett Stocks to Buy Now
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Is Dividend Yield and How Do You Calculate It?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.